Recently, the results of the 22nd China Patent Award evaluation by the China National Intellectual Property Administration (CNIPA) were announced. Suzhou SteriLance Medical Equipment Co., Ltd.'s "Disposable Safety Heel Incision Lancet" received the prestigious China Patent Excellence Award.

The China Patent Award, jointly presented by CNIPA and the World Intellectual Property Organization (WIPO), is the only governmental award in China specifically recognizing patented inventions and creations. It is highly authoritative, representative, and influential within China, and is endorsed by WIPO.

The awarded product, SteriLance Medical's "Disposable Safety Heel Incision Lancet," patent number: ZL200810023025.8, is specifically designed for clinical newborn genetic metabolic disorder screening. Known as the Infants Heel Incision Safety Lancet, this product features a unique patented design with an integrated safety lock for one-handed operation, a built-in microblade, and an arched incision that provides adequate blood volume without squeezing and minimizes scarring.

SteriHeel™ Plus Infants Heel Incision Safety Lancet

Driven by innovation and committed to intelligent manufacturing, SteriLance firmly believes that, amid the turbulent domestic and international markets, only with long-standing experience, rigorous quality pursuit, and relentless innovation can it lay a solid corporate foundation, achieving the status of a hidden champion in the medical consumables field and building a world-class, centennial SteriLance brand.

Did You Know? Due to genetic and environmental factors, some newborns may suffer from congenital metabolic disorders. Although some of these conditions may not show noticeable symptoms early on, they can be life-threatening and cause irreversible intellectual or physical damage if left untreated. To enable early detection and treatment, newborn screening was developed.

Newborn screening is mainly conducted by collecting blood spots from a newborn’s heel for testing. Traditional blood collection devices often cannot ensure blood quality, require certain skills to operate, and may cause skin injuries in infants. To address this, SteriLance developed the SteriHeel™ Plus Infants Heel Incision Safety Lancet, aimed at advancing newborn screening programs in China, increasing coverage rates of screened populations and test items, and improving the qualification rate of blood samples to make newborn screening a benefit to every Chinese family.

Comparison of Traditional Blood Collection Devices vs. SteriLance - SteriHeel™ Plus Infants Heel Incision Safety Lancet